

BioCopy Advances AI Driven Cancer Therapies with Strategic Investment from Haute Capital

Basel 16 March 2026

As part of a Series A financing round scheduled to close on March 31, 2026, Haute Capital Partners has made a strategic investment in BioCopy, reflecting their confidence in BioCopy's AI-powered drug development platform, particularly the advanced lung cancer drug candidate.

BioCopy AG, based in Basel, Switzerland, is transforming cancer drug discovery by combining artificial intelligence, automation, and precision screening technologies. The company targets previously unaddressable intracellular cancer mechanisms through peptide HLA biology, creating new antibody therapies for patients who currently have no treatment options.

Central to BioCopy's approach is its AI powered **ValidaTe**[®] platform, which profiles next generation anti-cancer candidates across thousands of cell targets. This pHLA focused system identifies the most promising candidates early, improving efficacy and safety while reducing the risk of later stage failures. A strong intellectual property portfolio, including granted patents on ultra-high throughput screening technologies and pending applications for novel drug candidates, targets, and AI based predictive tools underpin BioCopy's research strategy and competitive edge.

The company is advancing five antibody programs across solid tumors including lung, ovarian, bladder, liver, and breast cancers. The lead lung cancer program is progressing toward **IND readiness in 2027**, a key step toward clinical development.

"ValidaTe allows us to develop the most effective and safest drugs against intracellular cancer targets, with AI driven precision," said Dr. Matthias Wiedenfels, CEO of BioCopy AG. "The support from Haute Capital strengthens our ability to advance our portfolio toward more IND ready multi-specific drug candidates while continuing to explore previously untapped cancer targets. This investment underscores the strategic potential of our platform and our mission to bring effective therapies of utmost safety to patients who currently have no treatment options."

About BioCopy

BioCopy is a Swiss German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and development time of next generation biotherapeutics from approximately three years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases.

www.biocopy.com | LinkedIn

About Haute Capital Partners SA

Haute Capital Partners SA is a Swiss-listed investment company dedicated to creating long-term value through a diversified and forward-thinking approach. Listed on BX Swiss, it brings together private equity, digital assets, and quoted investments within a transparent and institutional-grade structure, offering both private and professional investors access to advanced financial opportunities in a responsible and innovative way. The company's registered shares are listed on the BX Swiss.

Ticker: HAUTE | ISIN: CH1115678950 | Valor: 111567895 | www.haute.com